33 results
Thumbnail

D2.114 - Occupational asthma and rhinitis in a worker in the single-use food packaging industry: challenges of multi-agent exposure

Thumbnail

D2.115 - Occupational asthma and rhinitis to isocyanates in industrial settings

Thumbnail

D2.105 - A Newly Identified Indoor Fungus, Fusarium hechiense, Modulates Allergic Airway Inflammation in a Murine Asthma Model

Thumbnail

D2.107 - Genotype–Phenotype Segregation in Chronic Rhinosinusitis with Nasal Polyp and associated comorbid Asthma: Multivariate Clustering of Interleukin-4, Interleukin-6, Interleukin-13, and TNF-α Variants with Type-2 Biomarkers and Clinical Traits

Thumbnail

D2.108 - Type 2 Inflammation Biomarkers in Patients with Chronic Rhinosinusitis with Nasal Polyps Under Treatment with Biologic Agents

Thumbnail

D2.109 - Single-Cell Sequencing Reveals the Immunological Mechanism of Astragaloside IV in the Treatment of Allergic Rhinitis Complicated with Asthma

Thumbnail

D2.110 - Real-world evaluation of tezepelumab in patients with severe asthma and chronic rhinosinusitis in France: preliminary results from the ROSE retrospective study

Thumbnail

D2.112 - The Impact of Inflammation on Protective Immune Responses in the Airways

Thumbnail

D2.113 - Comparison of Non-Asthmatic Allergic Rhinitis Patients with Normal and Low FEF25–75 Levels

Thumbnail

D2.120 - Missing the Red Flags? Identification of High-Risk Paediatric Asthma Admissions Following the 2024 BTS/NICE/SIGN Update

Thumbnail

D2.121 - Seroprotection to influenza virus in vaccinated patients with bronchial asthma on biological treatment

Thumbnail

D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child